Is Zosyn (piperacillin/tazobactam) effective against Bacteroides species?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Yes, Zosyn (piperacillin/tazobactam) is effective against Bacteroides species, including Bacteroides fragilis, as it combines piperacillin with tazobactam, a beta-lactamase inhibitor that enhances its activity against beta-lactamase-producing strains of Bacteroides 1.

Key Points to Consider

  • Zosyn's effectiveness against Bacteroides species is due to its mechanism of action, which involves inhibiting bacterial cell wall synthesis, making it valuable for treating mixed aerobic and anaerobic infections such as intra-abdominal infections 1.
  • The addition of tazobactam to piperacillin enhances its activity against beta-lactamase-producing strains of Bacteroides, which are resistant to many other beta-lactam antibiotics 1.
  • While resistance rates to Zosyn among Bacteroides species remain relatively low, it is crucial to consider local resistance patterns when selecting this antibiotic for serious infections 1.
  • The typical adult dosage of Zosyn is 3.375g or 4.5g administered intravenously every 6-8 hours, with adjustments needed for patients with renal impairment.

Clinical Use and Resistance

  • Zosyn is particularly useful for treating infections where Bacteroides species are often involved, such as intra-abdominal infections, complicated skin infections, and aspiration pneumonia 1.
  • The use of Zosyn should be guided by susceptibility testing and local epidemiology of resistance to ensure its effectiveness and to minimize the development of resistance 1.
  • As with all antibiotics, the use of Zosyn should be rational and appropriate to optimize clinical care and reduce the selection pressure on resistant pathogens 1.

From the FDA Drug Label

Piperacillin and tazobactam has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections ... Anaerobic bacteria Bacteroides fragilis group (B. fragilis, B. ovatus, B. thetaiotaomicron, and B. vulgatus)

Zosyn (piperacillin/tazobactam) is effective against Bacteroides species, including B. fragilis, B. ovatus, B. thetaiotaomicron, and B. vulgatus 2.

From the Research

Effectiveness of Zosyn against Bacteroides

  • Zosyn, also known as piperacillin/tazobactam, is a broad-spectrum antibiotic that covers a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, including Bacteroides species 3.
  • The combination of piperacillin and tazobactam provides effective coverage against many pathogens producing beta-lactamases, which are enzymes that can inactivate certain antibiotics 4.
  • Studies have shown that piperacillin/tazobactam is effective against Bacteroides species, including Bacteroides fragilis, which is a common cause of intra-abdominal infections 3, 4.
  • Piperacillin/tazobactam has been compared to other antibiotics, such as imipenem and ticarcillin/clavulanate, and has been shown to be equally or more effective in treating infections caused by Bacteroides species 3, 4.

Spectrum of Activity

  • The spectrum of activity of piperacillin/tazobactam includes:
    • Gram-positive aerobic bacteria, such as Staphylococcus aureus and Streptococcus pneumoniae
    • Gram-negative aerobic bacteria, such as Escherichia coli and Klebsiella pneumoniae
    • Anaerobic bacteria, such as Bacteroides fragilis and Clostridium difficile
  • Piperacillin/tazobactam is also effective against many bacteria that produce beta-lactamases, which can inactivate certain antibiotics 3, 4.

Clinical Use

  • Piperacillin/tazobactam is commonly used to treat a variety of infections, including:
    • Intra-abdominal infections, such as appendicitis and peritonitis
    • Skin and soft tissue infections, such as cellulitis and abscesses
    • Urinary tract infections, such as pyelonephritis and cystitis
    • Respiratory tract infections, such as pneumonia and bronchitis
  • Piperacillin/tazobactam may be used as an alternative to carbapenems in certain situations, such as in patients with ESBL-producing organisms 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Piperacillin/tazobactam: a critical review of the evolving clinical literature.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1996

Research

Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase-Producing Organisms?

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.